Our study results revealed an independent prognostic significance of pretreatment sPD-L1, thus confirming previous reports, but also highlighted serum VEGF-B, a biomarker relatively understudied as of yet, as a novel predictor of prognosis in ICI-treated advanced NSCLC. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.